β€’
Sep 30, 2023

Beauty Health Q3 2023 Earnings Report

Beauty Health reported net sales of $97.4 million, a 10% increase year-over-year, driven by APAC and EMEA, but was overshadowed by lower-than-expected U.S. revenue and $63.1 million in restructuring charges related to device upgrades.

Key Takeaways

Beauty Health's Q3 2023 net sales increased by 10% year-over-year to $97.4 million, driven by growth in APAC and EMEA. However, lower-than-expected U.S. revenue and $63.1 million in restructuring charges related to device upgrades impacted the quarter. The company is revising its fiscal year 2023 net sales guidance to $385 to $400 million and adjusted EBITDA margin guidance to 5% to 6%, and suspending its long-term 2025 financial outlook.

Net sales increased by 10% year-over-year to $97.4 million, driven by APAC and EMEA.

Gross margin was (12.9)%, impacted by Syndeo Program costs and obsolete product costs.

Net loss was $(73.8) million, primarily due to Syndeo Program costs.

Revised fiscal year 2023 net sales guidance to $385 to $400 million and adjusted EBITDA margin guidance to 5% to 6%.

Total Revenue
$97.4M
Previous year: $88.8M
+9.7%
EPS
-$0.09
Previous year: $0.05
-280.0%
Adjusted EBITDA
$9.1M
Previous year: $16.5M
-44.8%
Adjusted EBITDA Margin
9.3%
Previous year: 18.6%
-50.0%
Adjusted Gross Margin
62.5%
Previous year: 75.1%
-16.8%
Gross Profit
-$12.6M
Previous year: $61.6M
-120.5%
Cash and Equivalents
$559M
Previous year: $684M
-18.2%
Free Cash Flow
$17.8M
Total Assets
$973M
Previous year: $1.1B
-11.9%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

The Company revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million and adjusted EBITDA margin guidance to a range of 5% to 6%. The company suspended its long-term fiscal year 2025 outlook.

Positive Outlook

  • Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control.
  • Excludes any unannounced acquisitions, dispositions or financings.
  • Assumes a largely re-opened global market.
  • Assumes no material deterioration in foreign currency exchange rates.

Challenges Ahead

  • Revised fiscal year 2023 net sales guidance due to provider experience challenges with Syndeo creating lower than expected demand for delivery systems in the U.S.
  • Revised fiscal year 2023 adjusted EBITDA margin guidance as a result of slower than expected gross margin recovery and reduced fixed cost operating leverage.
  • Suspended its long-term fiscal year 2025 outlook.
  • Global market would be negatively impacted if closures related to COVID-19 or other restrictive measures are reimplemented.

Revenue & Expenses

Visualization of income flow from segment revenue to net income